tak 603 has been researched along with Graft-Versus-Host Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albring, J; Berdel, WE; Bisping, G; Kiehl, M; Kienast, J; Opitz, C; Pauels, HG; Poremba, C; Scheffold, C; Schlösser, V; Silling, G; Specht, C; Stelljes, M; Volkmann, S | 1 |
| Akiyama, T; Fujimi, A; Hirayama, Y; Kato, J; Kogawa, K; Kon, S; Konuma, Y; Kuroda, H; Kusakabe, T; Lu, Y; Matsunaga, T; Niitsu, Y; Nishiie, K; Sakamaki, S; Takemoto, N | 1 |
2 other study(ies) available for tak 603 and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Topics: Animals; Antigens, Neoplasm; Cell Proliferation; Cytokines; Graft vs Host Disease; Graft vs Tumor Effect; Isoantigens; Mice; Mice, Inbred Strains; Quinolines; Th1 Cells; Triazoles; Tumor Cells, Cultured | 2007 |
Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603.
Topics: Acute Disease; Administration, Oral; Animals; Bone Marrow Transplantation; Cytokines; Drug Evaluation, Preclinical; Female; Graft vs Host Disease; Immunosuppressive Agents; Intestines; Liver; Lymphocyte Count; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Quinolines; Radiation Chimera; Skin; Spleen; Th1 Cells; Transplantation, Homologous; Triazoles | 2001 |